{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:40:59Z","timestamp":1792482059693,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.canep.2026.103256","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:19:28Z","timestamp":1792466368000},"page":"103256","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Temporal evolution of gastric adenocarcinoma in the United States, 2000\u20132023: Incidence, presentation, registry-recorded treatment, and survival"],"prefix":"10.1016","volume":"105","author":[{"given":"Hongkun","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liaonan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canep.2026.103256_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canep.2026.103256_bib2","first-page":"209","article-title":"Global cancer statistics 2020","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canep.2026.103256_bib3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41571-023-00747-0","article-title":"HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention","volume":"20","author":"Thrift","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canep.2026.103256_bib4","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2026.103256_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101404","article-title":"The current and future incidence and mortality of gastric cancer in 185 countries, 2020\u201340","volume":"47","author":"Morgan","year":"2022","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.canep.2026.103256_bib6","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/gutjnl-2019-320234","article-title":"Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035","volume":"69","author":"Arnold","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.canep.2026.103256_bib7","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1001\/jama.2010.496","article-title":"Age-specific trends in incidence of noncardia gastric cancer in US adults","volume":"303","author":"Anderson","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.canep.2026.103256_bib8","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/jnci\/djx262","article-title":"The changing face of noncardia gastric cancer incidence among US non-Hispanic whites","volume":"110","author":"Anderson","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canep.2026.103256_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/MCG.0000000000001811","article-title":"Recent trends in the incidence of gastric cancer in the United States","volume":"58","author":"Liu","year":"2024","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.canep.2026.103256_bib10","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1016\/j.cgh.2023.01.037","article-title":"Epidemiology of gastric malignancies 2000\u20132018 according to histology: a population-based analysis of incidence and temporal trends","volume":"21","author":"Rustgi","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canep.2026.103256_bib11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1055-9965.EPI-22-0994","article-title":"Cancer progress and priorities: gastric cancer","volume":"32","author":"Alagesan","year":"2023","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.canep.2026.103256_bib12","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.3390\/cancers16172948","article-title":"Epidemiology of gastric cancer\u2013-changing trends and global disparities","volume":"16","author":"Inoue","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.canep.2026.103256_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41572-023-00431-8","article-title":"Helicobacter pylori infection","volume":"9","author":"Malfertheiner","year":"2023","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.canep.2026.103256_bib14","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1053\/j.gastro.2023.01.018","article-title":"Controlling gastric cancer in a world of heterogeneous risk","volume":"164","author":"Huang","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canep.2026.103256_bib15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1053\/j.gastro.2023.04.026","article-title":"Effect of Helicobacter pylori eradication therapy on the incidence of noncardia gastric adenocarcinoma in a large diverse population in the United States","volume":"165","author":"Li","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canep.2026.103256_bib16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1053\/j.gastro.2023.11.286","article-title":"The effect of nationwide organized cancer screening programs on gastric cancer mortality: a synthetic control study","volume":"166","author":"Sun","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canep.2026.103256_bib17","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/ijc.34415","article-title":"Incidence and mortality trends in gastric cancer in the United States, 1992\u20132019","volume":"152","author":"Chen","year":"2023","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.canep.2026.103256_bib18","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1158\/1055-9965.EPI-26-0241","article-title":"Trends in gastric cancer incidence, mortality, and survival by histologic subtype in the United States (2000\u20132022) and a contemporary Chinese cohort","volume":"35","author":"Yin","year":"2026","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.canep.2026.103256_bib19","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1111\/j.1572-0241.2006.00778.x","article-title":"Noncardia gastric adenocarcinoma remains an important and deadly cancer in the United States","volume":"101","author":"Lau","year":"2006","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.canep.2026.103256_bib20","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1245\/s10434-018-6627-y","article-title":"Survival trends in gastric adenocarcinoma: a population-based study in Sweden","volume":"25","author":"Asplund","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.canep.2026.103256_bib21","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/curroncol28010017","article-title":"Gastric cancer treatments and survival trends in the United States","volume":"28","author":"Stahl","year":"2021","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.canep.2026.103256_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.30018","article-title":"Incidence, stage, treatment, and survival of noncardia gastric cancer","volume":"6","author":"van Velzen","year":"2023","journal-title":"JAMA Netw. Open."},{"key":"10.1016\/j.canep.2026.103256_bib23","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1245\/s10434-017-5992-2","article-title":"Survival rates for patients with resected gastric adenocarcinoma finally have increased in the United States","volume":"24","author":"Arsoniadis","year":"2017","journal-title":"Ann. Surg. Oncol."},{"issue":"8","key":"10.1016\/j.canep.2026.103256_bib24","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/00365521.2019.1649456","article-title":"Prognostic factors in patients with gastric adenocarcinoma using competing-risk analysis: a study of cases in the SEER database","volume":"54","author":"Zhang","year":"2019","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.canep.2026.103256_bib25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cncr.35026","article-title":"Annual report to the nation on the status of cancer, part 2","volume":"130","author":"Negoita","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.canep.2026.103256_bib26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/jncimonographs\/lgae024","article-title":"Toward real-time reporting of cancer incidence: methodology, pilot study, and SEER Program implementation","volume":"2024","author":"Chen","year":"2024","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"10.1016\/j.canep.2026.103256_bib27","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The STROBE statement","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2026.103256_bib28","article-title":"The RECORD statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS. Med."},{"key":"10.1016\/j.canep.2026.103256_bib29","first-page":"50","article-title":"How to use the surveillance, epidemiology, and end results (SEER) data: research design and methodology","volume":"10","author":"Che","year":"2023","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.canep.2026.103256_bib30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates","volume":"19","author":"Kim","year":"2000","journal-title":"Stat. Med."},{"key":"10.1016\/j.canep.2026.103256_bib31","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1177\/0962280206070621","article-title":"Efficient interval estimation for age-adjusted cancer rates","volume":"15","author":"Tiwari","year":"2006","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.canep.2026.103256_bib32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.canep.2026.103256_bib33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"10.1016\/j.canep.2026.103256_bib34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"10.1016\/j.canep.2026.103256_bib35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.canep.2026.103256_bib36","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","article-title":"Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis","volume":"32","author":"Uno","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canep.2026.103256_bib37","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann. Stat."},{"key":"10.1016\/j.canep.2026.103256_bib38","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.canep.2026.103256_bib39","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO Clinical Practice Guideline","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canep.2026.103256_bib40","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer. 2023;26:1\u201325. doi:10.1007\/s10120-022-01331-8.","DOI":"10.1007\/s10120-022-01331-8"},{"key":"10.1016\/j.canep.2026.103256_bib41","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa010187","article-title":"Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction","volume":"345","author":"Macdonald","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canep.2026.103256_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canep.2026.103256_bib43","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa072252","article-title":"Adjuvant chemotherapy for gastric cancer with S-1","volume":"357","author":"Sakuramoto","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canep.2026.103256_bib44","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0140-6736(11)61873-4","article-title":"Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC)","volume":"379","author":"Bang","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2026.103256_bib45","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S1470-2045(18)30132-3","article-title":"Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS)","volume":"19","author":"Cats","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canep.2026.103256_bib46","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative FLOT versus ECF\/ECX for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4)","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2026.103256_bib47","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA)","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2026.103256_bib48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649)","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782126002729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782126002729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:24:07Z","timestamp":1792481047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782126002729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":48,"alternative-id":["S1877782126002729"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2026.103256","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temporal evolution of gastric adenocarcinoma in the United States, 2000\u20132023: Incidence, presentation, registry-recorded treatment, and survival","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2026.103256","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103256"}}